HK1051873A1 - Antigenic polypeptides - Google Patents

Antigenic polypeptides

Info

Publication number
HK1051873A1
HK1051873A1 HK03102366A HK03102366A HK1051873A1 HK 1051873 A1 HK1051873 A1 HK 1051873A1 HK 03102366 A HK03102366 A HK 03102366A HK 03102366 A HK03102366 A HK 03102366A HK 1051873 A1 HK1051873 A1 HK 1051873A1
Authority
HK
Hong Kong
Prior art keywords
polypeptides
antigenic polypeptides
antigenic
vaccines
identification
Prior art date
Application number
HK03102366A
Other languages
English (en)
Inventor
Foster Simon
Mcdowell Philip
Brummell Kirsty
Clarke Simon
Original Assignee
Univ Sheffield
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield, Biosynexus Inc filed Critical Univ Sheffield
Publication of HK1051873A1 publication Critical patent/HK1051873A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK03102366A 2000-06-20 2003-04-02 Antigenic polypeptides HK1051873A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0014907.0A GB0014907D0 (en) 2000-06-20 2000-06-20 Antigenic polypeptides
PCT/GB2001/002685 WO2001098499A1 (en) 2000-06-20 2001-06-20 Antigenic polypeptides

Publications (1)

Publication Number Publication Date
HK1051873A1 true HK1051873A1 (en) 2003-08-22

Family

ID=9893906

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03102366A HK1051873A1 (en) 2000-06-20 2003-04-02 Antigenic polypeptides

Country Status (13)

Country Link
US (3) US20030186275A1 (xx)
EP (4) EP1710311B1 (xx)
JP (2) JP2004500883A (xx)
CN (2) CN102021184A (xx)
AT (2) ATE524194T1 (xx)
AU (4) AU7424801A (xx)
BR (1) BR0111823A (xx)
CA (2) CA2805216A1 (xx)
DE (1) DE60132893T2 (xx)
GB (1) GB0014907D0 (xx)
HK (1) HK1051873A1 (xx)
NO (1) NO20025838L (xx)
WO (1) WO2001098499A1 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
MXPA03011701A (es) * 2001-06-15 2004-12-06 Nhibitex Inc Anticuerpos monoclonales y policlonales de reaccion que reconocen las proteinas de superficie a partir de estafilococos coagulasa-negativos y staphylococcus aureus.
WO2003011899A2 (en) * 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
US20140248273A1 (en) * 2001-09-08 2014-09-04 Jos van Strijp Vaccine based on staphylococcal superantigen-like 3 protein (ssl3)
WO2004013166A2 (en) * 2002-07-26 2004-02-12 Intercell Ag S. aureus antigene
US20060193866A1 (en) * 2003-04-22 2006-08-31 Intercell Ag H pylori antigens
NZ570750A (en) * 2003-07-24 2009-12-24 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
US20070134263A1 (en) * 2004-02-18 2007-06-14 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
FR2871237B1 (fr) * 2004-06-08 2011-03-11 Abag Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes
FR2871159A1 (fr) * 2004-06-08 2005-12-09 Abag Sa Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative
US8729013B2 (en) 2004-08-26 2014-05-20 The University Of Western Ontario Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
KR101359930B1 (ko) 2004-09-22 2014-02-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성조성물
AU2005333603A1 (en) * 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
AU2006206577B2 (en) 2005-01-21 2012-03-08 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
SG170090A1 (en) 2006-03-30 2011-04-29 Glaxosmithkline Biolog Sa Immunogenic composition
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
CA2744323A1 (en) * 2008-11-26 2010-06-03 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against staphylococcus aureus
EP2376111A4 (en) 2008-11-26 2013-01-09 Merck Sharp & Dohme POLYPEPTIDES FOR INDUCING PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
BRPI1010307B1 (pt) 2009-04-03 2021-07-27 University Of Chicago Polipeptídeos variantes de proteína a (spa), composição imunogênica compreendendo os mesmos, vacina, método de produção da referida vacina, bem como uso dos referidos polipeptídeos
ES2537437T3 (es) * 2009-05-18 2015-06-08 Julius-Maximilians-Universität Würzburg Anticuerpos o fragmentos de éstos dirigidos contra un epítopo del Staphylococcus aureus de IsaA o IsaB
CA2766629C (en) 2009-06-22 2020-03-24 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
US8747858B2 (en) 2010-07-13 2014-06-10 Merck Sharp & Dohme Corp. Staphylococcus aureus surface protein SA1789 and protective vaccine based thereon
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013034736A1 (en) * 2011-09-08 2013-03-14 Umc Utrecht Holding B.V. Use of staphylococcal superantigen- like 3 (ssl3) as an tlr2 inhibitor
WO2013066731A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2451 protein
CN104768572B (zh) 2012-04-26 2021-08-24 芝加哥大学 葡萄球菌凝固酶抗原及其使用方法
EP2872173A4 (en) 2012-07-10 2016-03-23 Merck Sharp & Dohme STAPHYLOCOCCUS AUREUS SA2493 PROTEIN PROTECTIVE VACCINE
WO2014013375A1 (en) 2012-07-16 2014-01-23 Pfizer Inc. Saccharides and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
WO1993007487A1 (fr) * 1991-10-09 1993-04-15 Iatron Laboratories, Inc. Procede de detection de staphylococcus aureus resistant au mesitylene, nouveau peptide, et adn le codant
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
WO1997014801A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel cell surface protein compounds
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
CA2255669A1 (en) * 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
GB9806762D0 (en) * 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
AU771426B2 (en) * 1998-08-31 2004-03-18 Inhibitex, Inc. Multicomponent vaccines
US6635473B1 (en) * 1998-08-31 2003-10-21 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus

Also Published As

Publication number Publication date
CN1437653A (zh) 2003-08-20
AU7424801A (en) 2002-01-02
EP2287316A1 (en) 2011-02-23
AU2010200510A1 (en) 2010-03-04
AU2007200937B8 (en) 2010-01-28
AU2001274248B2 (en) 2007-09-13
CA2805216A1 (en) 2001-12-27
US20060140979A1 (en) 2006-06-29
JP2012044991A (ja) 2012-03-08
CA2412504A1 (en) 2001-12-27
US20100166792A1 (en) 2010-07-01
AU2007200937A1 (en) 2007-03-22
EP2269634A3 (en) 2011-04-06
EP1292681B1 (en) 2008-02-20
AU2007200937B2 (en) 2009-11-12
EP1710311A3 (en) 2007-09-19
NO20025838D0 (no) 2002-12-05
AU2007200937A8 (en) 2010-01-28
DE60132893T2 (de) 2009-03-12
US7585658B2 (en) 2009-09-08
DE60132893D1 (de) 2008-04-03
CA2412504C (en) 2013-04-16
US20030186275A1 (en) 2003-10-02
NO20025838L (no) 2003-02-18
EP1292681A1 (en) 2003-03-19
WO2001098499A1 (en) 2001-12-27
EP2269634A2 (en) 2011-01-05
BR0111823A (pt) 2003-06-10
ATE524194T1 (de) 2011-09-15
CN102021184A (zh) 2011-04-20
GB0014907D0 (en) 2000-08-09
EP1710311B1 (en) 2011-09-14
ATE386806T1 (de) 2008-03-15
JP2004500883A (ja) 2004-01-15
US8568731B2 (en) 2013-10-29
EP1710311A2 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
HK1051873A1 (en) Antigenic polypeptides
AU2002355677A1 (en) Antigenic polypeptides
IL211037A0 (en) A method for identification, isolation and production of antigens to a specific pathogen
AP2001002199A0 (en) Novel streptococcus antigens
MXPA03000103A (es) Antigenos de streptococcus.
HK1087018A1 (en) Peptide-based passive immunization therapy for treatment of atherosclerosis
HK1043943A1 (zh) 肺炎鏈球菌蛋白質和疫苗
MXPA03001235A (es) Purificacion de antigenos vhb para uso en vacunas.
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
GB0008305D0 (en) Treatment of fungal infections
WO2003049765A3 (en) Enveloped virus vaccine and method for production
EP0744027A4 (en) HYDROPHILIC SIGNAL OLIGOPEPTIDES AND THEIR METHODS OF USE FOR THERAPEUTIC PURPOSES
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
WO2001004143A3 (en) Prostase vaccine
EP1304376A4 (en) PROCESS FOR PRODUCING RECOMBINANT PROTEIN
EP1090995A3 (en) Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof
EP1273655A4 (en) METHOD FOR PRODUCING A RECOMBINANT PROTEIN
GB0409559D0 (en) Polypeptide
WO2003025134A3 (en) mcFP ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF
DE60126490D1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
PL339513A1 (en) Vaccines against colonisation by campylobacter, antigenic campylobacter proteins and antibodies against campylobacter for said vaccines and method of obtaining the last mentioned ones
EP1467207A4 (en) SCREENING PROCESS
WO2001098459A3 (en) Hei-c encoding nucleic acids, polypeptides, antibodies and methods of use thereof
WO2001089454A3 (en) Proteus mirabilis-based vaccine
ECSP034474A (es) Nuevo tratamiento